Search Discussions

Main Content

  • tristajane
    so im in a study and the pills i take have no name on the bottle besides ''novartis'' and ever since i been taking them i have not been able to sleep no more than 4-5 without waking up due to very vivid nightmares ... my question is... is this normal ?
  • maria1
    side effects of drugs is common, some more serious than others. There must be someone in the study for you to contact to discuss this with. Also, are you eating sugar? When I indulge in a sugar snack I have dreams and nightmares. I dont know about sugar substitutes, if you use them, try not to to see if they are the reaction. Carbs can do it too, along with coffee and chocolate.

     
  • MS_Navigator_Steven
    Hello,

    This is Steve with the National MS Society. 

    I would encourage you to contact the study administrator to discuss this side-effect.  If it is effecting your sleep so severely, they may have you discontinue the pills.  I would also encourage you to talk with your neurologist about this.  

    If we can be of any assistnace, please do not hesitate to contact our Information Center at 1-800-344-4867.

    Take care,

    Steve
  • TheBillLarson
    Checking with the administrator of the study is by far the best suggestion. 

    I just checked the newest edition of the MS Research Update put out by the MS Association of America (MSAA). Novartis is the company that produces medications, not the medication itself. Novartis is the maker of the approved MS drug Gilenya which is an oral medication taken daily. The article notes that there is continued research on Gilenya even though it was approved in 2010 as a treatment for MS. 

    Novartis also has an experimental medication called Ofatumumab, a.k.a. Arzerra. This is administered intravenously and is also being studied via subcutaneous injection, so it is unlikely this is the study you are participating in.

    Novartis has a third medicine that they are researching for use with MS. It is called Siponimod now, but was previously identified as BAF312. This is an oral medication as well, somewhat similar to Gilenya being a S1P Receptor Modulator but different in that it doesn't stay in the body as long as Gilenya. Researchers hope that by not staying in the body as long, it will minimize the cardiac concerns that come with Gilenya.

    Assuming these are the primary projects Novartis is researching, I would think that the study you are participating in is for either Gilenya or Siponimod. My apologies for all of the technical terms; I took them right out of the MSAA publication. My recommendation would be to do your own research on the terms and the medications and see what information is out there. I would assume there is more available on Gilenya given it is approved.

    Best of luck to you. I hope some of this information proves useful for you. If you want to subscribe to the MSAA publication, just go to the MSAA website and see how to do so. I became a member at thier site (there is no charge) but I am not sure if membership is required to receive the publication.